InsiderTrades

Form 4 for AXGN Axogen, Inc.

Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-15 · accession 0000805928-25-000176 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-12-17 2025-12-15 AXGN Hartley Lindsey Marie CFO M - OptEx $8.27 +14.8K 46.2K +47% +$122.5K
D 2025-12-17 2025-12-15 AXGN Hartley Lindsey Marie CFO S - Sale+OE $29.86 -14.8K 31.4K -32% -$442.3K
D 2025-12-17 2025-12-15 AXGN Hartley Lindsey Marie CFO M - OptEx $0.00 -14.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-15 M A 14,812 $8.27 46,188 D — —
2 Common Common Stock 2025-12-15 S D 14,812 $29.86 31,376 D — — (F1) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.875 to $29.860 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3 Derivative Employee Stock Option (right to purchase) 2025-12-15 M D 14,812 $0.00 0 D $8.27 · — to 2033-03-16 14,812 Common Stock (F2) All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.